bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1712762
Sentiment: neutral
Topics: filing, disclosure
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K, likely with updates. Check for Reg FD disclosure.
AI Summary
On December 19, 2024, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates bioAffinity Technologies, Inc. is making a disclosure under Regulation FD and submitting exhibits, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain information that inherently increases risk.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (identifier) — Commission File Number
- 46-5211056 (identifier) — I.R.S. Employer Identification Number
- 3300 Nacogdoches Road , Suite 216 San Antonio , Texas 78217 (address) — Address of principal executive offices
- (210) 698-5334 (phone_number) — Business phone number
FAQ
What is the primary purpose of this 8-K filing for bioAffinity Technologies, Inc.?
The primary purpose is a Regulation FD Disclosure and the submission of Financial Statements and Exhibits, as indicated by the filing's item information.
On what date was the earliest event reported in this filing?
The date of the earliest event reported is December 19, 2024.
In which state was bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. was incorporated in Delaware.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number is 001-41463.
What is the address of bioAffinity Technologies, Inc.'s principal executive offices?
The address is 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-19 17:38:03
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 38KB
- 0001493152-24-050832.txt ( ) — 309KB
- biaf-20241219.xsd (EX-101.SCH) — 4KB
- biaf-20241219_def.xml (EX-101.DEF) — 29KB
- biaf-20241219_lab.xml (EX-101.LAB) — 36KB
- biaf-20241219_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer